Please assess the completion status of the following clinical trial:

Trial Title: Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 to 65 years;~* HBsAg seropositive status for more than 6 months prior to enrollment;~* never received treatment with any form of nucleos(t)ide analogues (NAs) or interferon before enrollment;~* Serum HBsAg ≤1500 IU/mL;~* HBeAg negative with or without HBeAb positive;~* Serum HBV DNA ≤2000IU/ml IU/mL;~* normal ALT levels;~* normal white blood cell and platelet counts;~* abdominal computed tomography or B-ultrasound showed no cirrhosis, splenomegaly or ascites.~Exclusion Criteria:~* Participants with other hepatotropic viruses or human immunodeficiency virus co-infection~* other chronic non-viral liver diseases or decompensated liver diseases~* tumours~* drug abuse~* severe psychiatric disease~* uncontrolled thyroid disease or diabetes~* pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): PegIFN α- 2b monotherapy, 180 μg/ week, 68 weeks of treatment, 24 weeks of follow-up after drug withdrawal
- Group B (Type: ACTIVE_COMPARATOR): Patients had a lead-in period of 16 weeks before baseline, pegifn α- 2b single drug treatment for 24 weeks, 4 weeks after drug withdrawal, 16 weeks of introduction period, pegifn α- 2b was followed up for 24 weeks. The plan of the induction period is as follows: 1) from the first day of the induction period, GM-CSF is injected subcutaneously ® one hundred μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd.), 100 μg/ day, 5 consecutive days, one cycle every 4 weeks, 4 consecutive cycles. 2) On the third day of the induction period, recombinant hepatitis B vaccine (Saccharomyces cerevisiae) (1.0ml/HBsAg 60 per dose) was injected subcutaneously μg. Shenzhen Kangtai Biological Products Co., Ltd.), 60 μ g. Once every 4 weeks for 4 consecutive cycles, the course of treatment was 68 weeks, and the patients were followed up for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).